Background
Methods
Cell lines and cell cultures
Patients and therapy response evaluation
Quantificational real-time polymerase chain reaction (qRT-PCR) for quantitative analysis of miR-150
Plasmid construction, lentivirus production and transduction
Cell proliferation assay
Clonogenic assay
Flow cytometry analysis of cell cycle and apoptosis
Luciferase reporter assay
Western blot (WB)
In vivo experiment
Statistical analysis
Results
Low levels of miR-150 were frequently found in NKTL tissues and cell lines
miR-150 expression was positively correlated with the treatment response of NKTL patients
miR-150 expression level | ||||
---|---|---|---|---|
All cases | Low expression | High expression | P value | |
Gender | 0.278 | |||
female | 16 | 12 (75%) | 4 (25%) | |
male | 20 | 12 (55%) | 8 (40%) | |
Age | 0.637 | |||
≥ 40 years | 15 | 10 (66.7%) | 5 (33.3%) | |
< 40 years | 21 | 14 (77.8%) | 7 (22.2%) | |
Therapy response | 0.000 | |||
CR | 12 | 3 (25%) | 9 (75%) | |
Non-CR | 24 | 21 (87.5%) | 3 (12.5%) | |
Clinical stage | 0.133 | |||
I | 3 | 1 (33.3%) | 2 (66.7%) | |
II | 7 | 3 (42.8%) | 4 (57.2%) | |
III | 18 | 15 (83.4%) | 3 (16.6%) | |
IV | 8 | 5 (62.5%) | 3 (37.5%) | |
IPI stage | 0.853 | |||
1 | 18 | 13 (72.2%) | 5 (27.7%) | |
2 | 14 | 9 (64.2%) | 5 (35.7%) | |
3 | 2 | 1 (50%) | 1 (50%) | |
4 | 2 | 1 (50%) | 1 (50%) | |
EBV | 0.007 | |||
normal | 10 | 3 (30%) | 7 (70%) | |
increase | 26 | 21 (80.7%) | 5 (19.2%) |
miR-150 enhanced the sensitivity of NKTL cells to IR
Groups | D0 | Dq | SF2 | SERD0 | SERDq | SERsF2 |
---|---|---|---|---|---|---|
Control | 2.7 | 0.37 | 0.474 | – | – | – |
miR-150 | 1.98 | 0.18 | 0.417 | 1.363 | 2.050 | 1.064 |